Peptide Hormones in Diagnosing and Treating Gastroenteropancreatic Neuroendocrine Tumors | Research

The takeaway

Peptide biomarkers like insulin, glucagon, somatostatin, and ghrelin are central to diagnosing neuroendocrine tumors, while somatostatin analogues remain the first-line medical therapy for these cancers.

85-98% sensitivity
NETest measuring 51 neuroendocrine marker genes in blood can detect gastrointestinal neuroendocrine tumors with high accuracy

What the researchers found

Peptide hormone biomarkers are central to NEN diagnosis, and somatostatin analogues are first-line medical therapy. NETest (measuring 51 marker genes) achieves 85-98% sensitivity and 93-97% specificity for detecting gastrointestinal NENs.

Why it matters

Neuroendocrine tumors are increasing in incidence and require peptide-based diagnostics and treatments. Understanding which hormones to measure and how somatostatin analogues work is essential for proper management.

The numbers in context

NETest: 85-98% sensitivity, 93-97% specificity, 51 marker genes; biomarkers: insulin, glucagon, VIP, gastrin, somatostatin, 5-HIAA; somatostatin analogs first-line

How the study worked

Narrative review of pathophysiology, diagnostic algorithms, and management of gastroenteropancreatic neuroendocrine neoplasms.

Who was studied

Review of GEP neuroendocrine neoplasm literature

What this study cannot tell us

Narrative review with no new data. NEN management is highly specialized and individualized. Some emerging biomarkers require further validation in large prospective studies.

How to read the evidence

Not applicable (narrative review). Synthesizes current evidence on NEN diagnosis and management.

When this study was published

Published 2021. NEN diagnostic and treatment approaches continue to evolve with new targeted therapies and biomarker technologies.

The bigger picture

NENs highlight how peptide hormones serve dual roles — as the products of these tumors (causing symptoms) and as the basis for their treatment (somatostatin analogues). The field is moving toward multi-gene liquid biopsies that could transform cancer monitoring.

Questions still open

Will NETest replace traditional single-biomarker testing for NEN diagnosis and monitoring?
Could next-generation somatostatin analogues with improved receptor selectivity offer better tumor control?
How should NEN management change as liquid biopsy technologies mature?

Common questions

What are neuroendocrine tumors?

Neuroendocrine tumors grow from hormone-producing cells in the gut and pancreas. They can produce excess peptide hormones like insulin or glucagon, causing specific symptoms. Most are slow-growing but require careful monitoring and treatment.

How do somatostatin analogues treat these tumors?

Somatostatin analogues are synthetic versions of the natural peptide hormone somatostatin, which normally suppresses hormone secretion. When given as medication, they reduce the excess hormone production causing symptoms and can slow tumor growth in many patients.

Read the original research

Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot.

World journal of gastrointestinal surgery, 13(3), 231-255

View on PubMed ↗Publisher’s paper ↗

Citation

Fernandez, Cornelius J; Agarwal, Mayuri; Pottakkat, Biju; Haroon, Nisha Nigil; George, Annu Susan; Pappachan, Joseph M. (2021). Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot.. World journal of gastrointestinal surgery, 13(3), 231-255. https://doi.org/10.4240/wjgs.v13.i3.231